Skip to main content

Table 4 Multivariate analysis of factors associated with DFS and OS in pre/peri- menopausal patients

From: Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients

Characteristics DFS OS
HR (95% CI) P value HR (95% CI) P value
Neo-adjuvant therapy (Yes vs. No) 3.74 (2.56–5.46) <  0.001 2.27 (1.22–4.21) 0.009
Breast surgery (BCS vs. Mastectomy) 0.84 (0.59–1.21) 0.841 0.42 (0.17–1.00) 0.050
Tumor size (>  2.0 cm vs. ≤ 2.0 cm) 1.84 (1.34–2.51) <  0.001 2.89 (1.46–5.71) 0.002
ALN status (Positive vs. Negative) 1.14 (0.78–1.65) 0.503 2.10 (1.16–3.83) 0.015
Histological grade   0.328   0.013
III vs. I/II 1.30 (0.92–1.84)   2.45 (1.34–4.50)  
NA vs. I/II 1.06 (0.65–1.71)   1.92 (0.87–4.27)  
LVI (Yes vs. No) 1.76 (1.16–2.67) 0.008 1.82 (0.87–3.82) 0.112
ER   0.146   0.055
10–49% vs. 1–9% 0.96 (0.47–1.93)   0.65 (0.25–1.73)  
≥ 50% vs. 1–9% 0.70 (0.35–1.39)   0.37 (0.14–0.98)  
PR (≥ 20% vs. <  20%) 0.86 (0.62–1.20) 0.384 0.83 (0.44–1.55) 0.559
Ki-67 (≥ 14% vs. <  14%) 1.51 (1.09–2.09) 0.013 / /
Radiotherapy (Yes vs. No) 1.23 (0.86–1.77) 0.254 / /
Chemotherapy (Yes vs. No) 1.50 (1.04–2.17) 0.032 / /
Endocrine therapy (Yes vs. No) 0.41 (0.26–0.62) <  0.001 0.37 (0.19–0.73) 0.004
Group (HER2-pos-T vs. HER2-neg) 0.56 (0.36–0.89) 0.013 0.46 (0.19–1.10) 0.080
  1. HER2, human epidermal growth factor receptor 2; BCS, breast-conserving surgery; ALN, axillary lymph node; LVI, lymph-vascular invasion; ER, estrogen receptor; PR, progesterone receptor; y/o, years old